These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22470921)

  • 1. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
    de Paula EV; Kavakli K; Mahlangu J; Ayob Y; Lentz SR; Morfini M; Nemes L; Šalek SZ; Shima M; Windyga J; Ehrenforth S; Chuansumrit A;
    J Thromb Haemost; 2012 Jan; 10(1):81-9. PubMed ID: 22470921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
    Lentz SR; Ehrenforth S; Karim FA; Matsushita T; Weldingh KN; Windyga J; Mahlangu JN;
    J Thromb Haemost; 2014 Aug; 12(8):1244-53. PubMed ID: 24931322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
    Mahlangu JN; Weldingh KN; Lentz SR; Kaicker S; Karim FA; Matsushita T; Recht M; Tomczak W; Windyga J; Ehrenforth S; Knobe K;
    J Thromb Haemost; 2015 Nov; 13(11):1989-98. PubMed ID: 26362483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
    Ljung R; Karim FA; Saxena K; Suzuki T; Arkhammar P; Rosholm A; Giangrande P;
    J Thromb Haemost; 2013 Jul; 11(7):1260-8. PubMed ID: 23578227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
    Brophy DF; Martin EJ; Barrett JC; Nolte ME; Kuhn JG; Hedner U; Ezban M
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vatreptacog alfa from conception to clinical proof of concept.
    Persson E; Olsen OH; Bjørn SE; Ezban M
    Semin Thromb Hemost; 2012 Apr; 38(3):274-81. PubMed ID: 22510860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
    Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
    J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
    Croom KF; McCormack PL
    BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
    Agersø H; Tranholm M
    Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
    Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
    Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
    Santagostino E; Mancuso ME; Rocino A; Mancuso G; Scaraggi F; Mannucci PM
    J Thromb Haemost; 2006 Feb; 4(2):367-71. PubMed ID: 16420567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.
    Lentz SR; Rangarajan S; Karim FA; Andersen PD; Arkhammar P; Rosu G; Mahlangu J
    Blood Coagul Fibrinolysis; 2017 Apr; 28(3):224-229. PubMed ID: 27427786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
    Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
    Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.
    Chambost H; Santagostino E; Laffan M; Kavakli K;
    Haemophilia; 2013 Jul; 19(4):571-7. PubMed ID: 23557542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
    Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; Lemm G
    J Thromb Haemost; 2012 May; 10(5):773-80. PubMed ID: 22353395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.